Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and treatment of myeloma and its manifestations

被引:198
作者
Yaccoby, S [1 ]
Barlogie, B [1 ]
Epstein, J [1 ]
机构
[1] Univ Arkansas Med Sci, Arkansas Canc Res Ctr, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA
关键词
D O I
10.1182/blood.V92.8.2908.420a32_2908_2913
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Progress in unraveling the biology of myeloma has suffered from lack of an in vitro or in vivo system for reproducible growth of myeloma cells and development of disease manifestations. The SCID-hu mouse harbors a human microenvironment in the form of human fetal bone. Myeloma cells from the bone marrow of 80% of patients readily grew in the human environment of SCID-hu mice. Engraftment of myeloma cells was followed by detectable human Ig levels in the murine blood. Myeloma-bearing mice had high levels of monotypic human Igs, high blood calcium levels, increased osteoclast activity, and severe resorption of the human bones. The human microenvironment was infiltrated with Epstein-Barr virus-negative monoclonal myeloma cells of the same clonality as the original myeloma cells. Active angiogenesis was apparent in areas of myeloma cell infiltration; the new endothelial cells were of human origin. We conclude that the SCID-hu mouse is a favorable host for studying the biology and therapy of myeloma and that a normal bone marrow environment can support the growth of myeloma cells. (C) 1998 by The American Society of Hematology.
引用
收藏
页码:2908 / 2913
页数:6
相关论文
共 31 条
[1]   Development of an in vivo model of human multiple myeloma bone disease [J].
Alsina, M ;
Boyce, B ;
Devlin, RD ;
Anderson, JL ;
Craig, F ;
Mundy, GR ;
Roodman, GD .
BLOOD, 1996, 87 (04) :1495-1501
[2]   Development of an orthotopic SCID mouse-human tumor xenograft model displaying the multidrug-resistant phenotype [J].
Bellamy, WT ;
Mendibles, P ;
Bontje, P ;
Richter, FTL ;
Weinstein, RS ;
Grogan, TM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 37 (04) :305-316
[3]  
BELLAMY WT, 1993, AM J PATHOL, V142, P691
[4]   INTERLEUKIN-3 AND INTERLEUKIN-6 SYNERGISTICALLY PROMOTE THE PROLIFERATION AND DIFFERENTIATION OF MALIGNANT PLASMA-CELL PRECURSORS IN MULTIPLE-MYELOMA [J].
BERGUI, L ;
SCHENA, M ;
GAIDANO, G ;
RIVA, M ;
CALIGARISCAPPIO, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (02) :613-618
[5]  
BILLADEAU D, 1991, BLOOD, V78, P3021
[6]   THE BONE-MARROW OF MULTIPLE-MYELOMA PATIENTS CONTAINS B-CELL POPULATIONS AT DIFFERENT STAGES OF DIFFERENTIATION THAT ARE CLONALLY RELATED TO THE MALIGNANT PLASMA-CELL [J].
BILLADEAU, D ;
AHMANN, G ;
GREIPP, P ;
VANNESS, B .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (03) :1023-1031
[7]   IDIOTYPIC OLIGONUCLEOTIDE PROBES TO DETECT MYELOMA CELLS BY MESSENGER-RNA IN-SITU HYBRIDIZATION [J].
BROWN, R ;
LUO, XF ;
GIBSON, J ;
MORLEY, A ;
SYKES, P ;
BRISCO, M ;
JOSHUA, D .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (01) :113-118
[8]   THE C.B.17 SCID MOUSE STRAIN AS A MODEL FOR HUMAN DISSEMINATED LEUKEMIA AND MYELOMA IN-VIVO [J].
CATTAN, AR ;
DOUGLAS, E .
LEUKEMIA RESEARCH, 1994, 18 (07) :513-522
[9]   Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cells [J].
Chen, BZJ ;
Epstein, J .
BLOOD, 1996, 87 (05) :1972-1976
[10]   EVIDENCE FOR A BONE-MARROW B-CELL TRANSCRIBING MALIGNANT PLASMA-CELL VDJ JOINED TO C-MU SEQUENCE IN IMMUNOGLOBULIN (IGG)-SECRETING AND IGA-SECRETING MULTIPLE MYELOMAS [J].
CORRADINI, P ;
BOCCADORO, M ;
VOENA, C ;
PILERI, A .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (03) :1091-1096